Compare · GAUZ vs TMO
GAUZ vs TMO
Side-by-side comparison of Gauzy Ltd. (GAUZ) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- GAUZ operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $197.88B, about 28550.9x GAUZ ($6.9M).
- Over the past year, GAUZ is down 94.5% and TMO is up 28.1% - TMO leads by 122.6 points.
- TMO has hit the wire 9 times in the past 4 weeks while GAUZ has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 6 for GAUZ).
- Company
- Gauzy Ltd.
- Thermo Fisher Scientific Inc
- Price
- $0.38+0.68%
- $532.16-2.05%
- Market cap
- $6.9M
- $197.88B
- 1M return
- -40.22%
- +12.59%
- 1Y return
- -94.52%
- +28.12%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 0
- 9
- Recent ratings
- 6
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest GAUZ
- SEC Form SEC STAFF ACTION filed by Gauzy Ltd.
- SEC Form 6-K filed by Gauzy Ltd.
- Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F
- Amendment: SEC Form SCHEDULE 13G/A filed by Gauzy Ltd.
- SEC Form NT 20-F filed by Gauzy Ltd.
- SEC Form 6-K filed by Gauzy Ltd.
- SEC Form 6-K filed by Gauzy Ltd.
- Gauzy Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
- SEC Form 6-K filed by Gauzy Ltd.
- Gauzy Strengthens Board and Regains Compliance with Nasdaq Listing Requirements
Latest TMO
- Thermo Fisher Scientific Announces Quarterly Dividend
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Keith R. Alexandra
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- Bernstein resumed coverage on Thermo Fisher with a new price target
- SEC Form 11-K filed by Thermo Fisher Scientific Inc
- Piper Sandler initiated coverage on Thermo Fisher with a new price target